Gorial F. I., Mashhadani S., et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial). Published online July 8, 2020.  https://doi.org/10.1101/2020.07.07.20145979 

Northwestern University

- Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report
- Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
- Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial
- Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice

Articles from Preprint (MedRxiv) about treatment interventions for COVID-19

Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. Published online January 1, 2020:2020.06.22.20137273. doi:10.1101/2020.06.22.20137273

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., Yan, D., . . . Zhang, Z. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. MedRxiv. https://doi.org/10.1101/2020.03.22.20040758.this

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial (Reference Info)

Karhadkar, T. R., Pilling, D., & Gomer, R. H. (2020). Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice. BioRxiv, 2020.08.26.269183. https://doi.org/10.1101/2020.08.26.269183


Learn Before

Related